Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,543 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,536 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05494411 | Named Patient Program for Mitomycin for Pyelocalyceal Solution | available | — | — | UroGen Pharma Ltd.INDUSTRY | 0 | Sep 15, 2026 | clinicaltrials |
| NCT06443944 | An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG | available | — | — | CG Oncology, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | available | — | — | Agenus Inc.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT06810141 | ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer | available | — | — | ImmunityBio, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07502716 | Compassionate Use of Ubamatamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor(KEAP) | available | — | — | Karyopharm Therapeutics IncINDUSTRY | 0 | Mar 2, 2026 | clinicaltrials |
| NCT06836648 | Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer | available | — | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05974410 | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | available | — | — | AVM Biotechnology IncINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT05650476 | Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) | available | — | — | PfizerINDUSTRY | 0 | Jun 12, 2025 | clinicaltrials |
| NCT05612191 | Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial) | available | — | — | Advenchen Laboratories, LLCINDUSTRY | 0 | Nov 28, 2022 | clinicaltrials |
| NCT04337099 | A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer | available | — | — | Matrix Biomed, Inc.INDUSTRY | 1 | May 5, 2021 | clinicaltrials |
| NCT01267461 | Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells | available | — | — | Meir Medical CenterOTHER | 0 | Aug 10, 2012 | clinicaltrials |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials